News
Select year:
2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016
Subscribe | Managers Transactions | News in Danish
May 09, 2023 | Company Announcements
Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme ObligationsMay 09, 2023 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Three Months of 2023April 11, 2023 | Company Announcements
Bavarian Nordic Completes Case Accrual for RSV Phase 3 Clinical TrialMarch 30, 2023 | Company Announcements
Resolutions of the Annual General Meeting 2023 of Bavarian Nordic A/SMarch 16, 2023 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant ExerciseMarch 07, 2023 | Company Announcements
Bavarian Nordic A/S – Notice Convening Annual General Meeting March 02, 2023 | Company Announcements
Bavarian Nordic Publishes Annual Report 2022February 23, 2023 | Company Announcements
Bavarian Nordic A/S - Registration of Share Capital Increase of 7,046,839 New Shares CompletedFebruary 20, 2023 | Company Announcements
Bavarian Nordic A/S Announces Completion of Directed Issue of 7,046,839 New Ordinary SharesFebruary 20, 2023 | Company Announcements
Bavarian Nordic A/S Launches Offering of up to 7,046,839 New Shares in a Directed Issue February 15, 2023 | Company Announcements
Bavarian Nordic to Acquire Portfolio of Travel Vaccines from Emergent BioSolutionsFebruary 15, 2023 | Company Announcements
Bavarian Nordic Provides Pipeline Update and Financial Guidance for 2023January 16, 2023 | Company Announcements
Bavarian Nordic Reports Better Than Expected Preliminary Financial Results for 2022December 23, 2022 | Company Announcements
Bavarian Nordic Enters Agreement Valued up to USD 83 Million with the U.S. Department of Defense to Further Advance the Development of Equine Encephalitis Virus VaccineDecember 08, 2022 | Company Announcements
New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic November 23, 2022 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant ExerciseNovember 17, 2022 | Company Announcements
Bavarian Nordic Enters Joint Procurement Agreement with the European Health Emergency Preparedness and Response Authority (HERA) for Monkeypox VaccinesNovember 09, 2022 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Nine Months of 2022October 17, 2022 | Company Announcements
Bavarian Nordic’s COVID-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial September 20, 2022 | Company Announcements
Luc Debruyne Appointed as Observer to the Board of Directors of Bavarian Nordic September 20, 2022 | Company Announcements
Bavarian Nordic Awarded Ten-Year Contract Amendment valued up to USD 434 million for the Supply of Smallpox and Monkeypox Vaccine to CanadaSeptember 07, 2022 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant ExerciseSeptember 07, 2022 | Company Announcements
Bavarian Nordic Enters Additional Monkeypox Vaccine Supply Contract with the European Health Emergency Preparedness and Response Authority (HERA) September 02, 2022 | Company Announcements
Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine CandidateAugust 24, 2022 | Company Announcements
Bavarian Nordic Announces First Half 2022 Results